OncoBeta | Top MedTech Solution Company in Europe 2018

MedTech Outlook Magazine

OncoBeta
Commercialized Radioisotope Cancer Therapy

CIO VendorShannon D Brown III, CEO
"I’m a nine-time Basal-Cell Cancer survivor myself,” states Shannon D Brown III, CEO, OncoBeta® GmbH, during an intense discussion about the causes and repercussions of non-melanoma skin cancers. Sources have revealed that approximately five million fall ill to non-melanoma skin cancer every year and the rise in skin cancer incidence has been 300 percent since 1994. The personal trauma of experiencing one of the most underestimated ailments known probably inspired Brown to devise an unconventional resolve to mitigate the wrath of skin cancers. “We are one of the first healthcare service providers to have successfully developed and commercialized radioisotope therapy for the treatment of non-melanoma skin cancer,” states Brown, highlighting the uniqueness of his firm.

In the recent past, the Germany-based organization has garnered significant visibility for its flagship, the Rhenium-SCT® (Skin Cancer Therapy). The therapy utilizes the radioisotope, Rhenium-188, which penetrates to a depth of 2-3 mm into the skin tissue and reaches the tumor region, leaving the healthy cells below unaffected. The greatest advantage of the OncoBeta® therapy is its non-invasive, painless nature, and the ability to treat malignant cancers effortlessly. Unlike traditional cancer treatment approaches, patients adopting the OncoBeta® way can read books or flip television channels and websites during therapy, making it less frightening or troublesome and more of a pleasurable experience. Depending on the size of the tumor, most patients have been treated in just a single instance without recurrence and without the need for additional, post-surgery care, a norm with most traditional cancer therapies. Brown recalls an instance where the Rhenium-SCT healed a patient with around twenty-seven lesions in just one sitting, emphasizing the potential of OncoBeta’s therapy better.
Within a short span, the German firm’s unique therapy approach has been adopted by several reputed healthcare solution providers. Consulting dermatologists help patients identify skin areas marred by cancerous tissues, and work close with healthcare institutions in deciding the kind of therapy needed and subsequent adoption of OncoBeta’s solution.

OncoBeta® is one of the first healthcare service providers to have successfully developed and commercialized radioisotope therapy for the treatment of non-melanoma skin cancer


OncoBeta’s finesse in delivering cutting-edge solutions has made it the trusted partner of several firms worldwide and its clientele includes quite a few eminent names. In a short period of time, the company has garnered the reputation of being one of the ‘go-to’ vendors among healthcare professionals for the treatment of Basal- und Squamous- Cell Carcinomas. Brown testifies the capabilities of his firm better by recalling its collaboration with the Nuclear Medicine Department of the University of Bologna, based in Italy. Joining hands with OncoBeta® helped the educational institution foray together with their dermatology department for the first time and thus, deliver non-invasive treatment of non-melanoma skin cancer. The assistance of the German healthcare services provider supports the University of Pretoria & Steve Biko Academic Hospital, through one of its distributors Tautomer, render its services to individuals in South Africa, a nation known for one of the largest number of non-melanoma skin cancer victim populations per capita.

Brown believes that there still exists a large market segment that has been untapped and his team is putting its best foot forward to reach out to physicians and healthcare institutions across the globe. “The company intends to expand its presence to the rest of Europe, Africa, Australia, North and South America, as well as the Asian markets in the days to come,” concludes Brown, revealing a glimpse of the company’s roadmap. Several healthcare patrons have backed OncoBeta® with funds to propel cancer therapy efforts and the accomplishment has largely motivated the firm’s team.

Top 20 MedTech Solution Companies in Europe - 2018

Company
OncoBeta

Management
Shannon D Brown III, CEO

Description
OncoBeta® is known for commercialization of radioisotope cancer therapy and treatment of skin cancer in a non-invasive and painless manner

OncoBeta News

GenesisCare and OncoBeta announce partnership to provide innovative treatment for non-melanoma skin cancer

Non-invasive therapy for non-melanoma skin cancer is now available at select GenesisCare treatment sites
MUNICH & SYDNEY - PRLog -- OncoBeta® GmbH, a commercial stage medical device company specialized in innovative epidermal radioisotope therapies. And GenesisCare, the largest provider of cancer care in Australia, the UK and Spain are excited to announce a partnership to provide an innovative, non-invasive, single-session treatment for non-melanoma skin cancer. OncoBeta and GenesisCare have recently completed recruitment of a phase 4 clinical trial and are now expanding access to suitable skin cancer patients.
Starting in June 2023 GenesisCare will offer the new therapy from their Tugan clinic, at John Flynn Private Hospital Gold Coast. This will be followed shortly after by GenesisCare clinics at Murdoch at St John of God Hospital – Perth, Chermside Medical Complex – Brisbane, Hurstville at Waratah Private Hospital – Sydney, and Cabrini Hospital – Melbourne.
Australia has the highest incidence of non-melanoma skin cancer in the world, with 32% of Australians treated for non-melanoma skin cancer each year. Recent data indicated that 70% of Australians will have at least one non-melanoma skin cancer excised. People with a history of skin cancer have a greatly elevated risk of developing new lesions. Currently used standard of care surgical treatment options can be scarring and disfiguring. OncoBeta's technology will offer a new and effective treatment option to address this large Australian medical burden.
Nicholas H. Vetter, OncoBeta Group CEO, stated, "This is a huge step forward for our organization. We are very excited about working together with GenesisCare to bring our technology for treating non-melanoma skin cancer to Australia. GenesisCare is a strong partner we look forward to collaborating with to reach thousands of Australians afflicted with non-melanoma skin cancer."
"The partnership with GenesisCare is a significant milestone for OncoBeta in Australia," said Shannon D. Brown III, CEO and Managing Director at OncoBeta® GmbH. "This will enhance access to precise, individualised treatments for non-melanoma skin cancer patients. The partnership aligns with our company's vision to improve quality of life for non-melanoma skin cancer patients across Australia."
GenesisCare Chief Medical Officer, Dr Marie Burke, stated, "We are looking forward to Australian patients having access to OncoBeta's innovative treatment for non-melanoma skin cancers. This fits well into the treatment portfolio offered at GenesisCare sites and represents a promising new option for certain patients with skin cancer that may be suitable for the single-session, non-invasive treatment."
Always talk to your doctor about what treatment options are suitable for you.
Healthcare Professionals can contact GenesisCare or OncoBeta for more information.